Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(6), P. 2054 - 2054

Published: March 18, 2025

MicroRNAs (miRNAs) have emerged as crucial regulators in digestive pathologies, including inflammatory bowel disease (miR-31, miR-155, and miR-21), colorectal cancer (miR-21, miR-598, miR-494), non-alcoholic fatty liver miR-192, miR-122). Their capacity to modulate gene expression at the post-transcriptional level makes them highly promising candidates for biomarkers therapeutic interventions. However, despite considerable progress, their clinical application remains challenging. Research has shown that miRNA is dynamic, varying across patients, stages, different intestinal regions. dual function both oncogenes tumor suppressors further complicates use, targeting miRNAs may yield unpredictable effects. Additionally, while miRNA-based therapies hold great potential, significant hurdles persist, off-target effects, immune activation, inefficiencies delivery methods. The intricate interplay between gut microbiota adds another layer of complexity, influencing mechanisms treatment responses. This review examined role emphasizing diagnostic potential. While they offer new avenues management, unresolved challenges underscore need research refine application.

Language: Английский